Literature DB >> 18953566

Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.

Gianluca Marucci1, Luca Morandi, Elisabetta Magrini, Anna Farnedi, Enrico Franceschi, Rossella Miglio, Daniela Calò, Annalisa Pession, Maria P Foschini, Vincenzo Eusebi.   

Abstract

Thirty-nine glial tumours (28 glioblastomas (GB) and 11 low-grade gliomas) were investigated with DNA microarrays to reveal a possible specific gene expression profile. Unsupervised classification through hierarchical cluster analysis identified two groups of tumours, the first composed of low-grade gliomas and the second mainly composed of GB. Nine genes were identified as most informative: seven were over-expressed in low-grade gliomas and under-expressed in GB; on the contrary, two genes, insulin-like growth factor binding protein 2 (IGFBP-2) and cell division cycle 20 homologue (CDC20), were over-expressed in GB and under-expressed in low-grade tumours. This same genetic profile was confirmed by reverse transcriptase polymerase chain reaction. Immunohistochemistry for IGFBP-2 was positive in 88.8% of the cases of GB and in only one low-grade glioma, whilst CDC20 immunostained 74.1% of the cases of GB and none low-grade glioma. This was confirmed in an additional series of cases studied with immunohistochemistry only. In conclusion, over-expression of mRNA levels of IGFBP-2 and CDC20 is highly related to GB, IGFBP-2 and CDC-20 gene and protein expressions are strongly correlated, and IGFBP-2 and CDC20 immunopositivity can be useful for the identification of GB in small biopsies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953566     DOI: 10.1007/s00428-008-0685-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  33 in total

1.  Normalization of cDNA microarray data.

Authors:  Gordon K Smyth; Terry Speed
Journal:  Methods       Date:  2003-12       Impact factor: 3.608

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium.

Authors:  Elin Richardsen; Tanja Ukkonen; Tone Bjørnsen; Elin Mortensen; Lars Egevad; Christer Busch
Journal:  Virchows Arch       Date:  2003-04-01       Impact factor: 4.064

4.  Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor.

Authors:  A Flyvbjerg; O Mogensen; B Mogensen; O S Nielsen
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

6.  Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.

Authors:  Véronique Ouellet; Marie-Claude Guyot; Cécile Le Page; Abdelali Filali-Mouhim; Christian Lussier; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

7.  In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade.

Authors:  M W Elmlinger; M H Deininger; B S Schuett; R Meyermann; F Duffner; E H Grote; M B Ranke
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

8.  Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G1.

Authors:  G Fang; H Yu; M W Kirschner
Journal:  Mol Cell       Date:  1998-08       Impact factor: 17.970

9.  Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability.

Authors:  Bibo Yuan; Yi Xu; Ju-Hyung Woo; Yunyue Wang; Young Kyung Bae; Dae-Sung Yoon; Robert P Wersto; Ellen Tully; Kathleen Wilsbach; Edward Gabrielson
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  38 in total

1.  Genome Wide Analysis of WD40 Proteins in Saccharomyces cerevisiae and Their Orthologs in Candida albicans.

Authors:  Buddhi Prakash Jain
Journal:  Protein J       Date:  2019-02       Impact factor: 2.371

2.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Authors:  Vassiliki Kotoula; Sofia Lambaki; Despina Televantou; Anna Kalogera-Fountzila; Angelos Nikolaou; Konstantinos Markou; Despina Misailidou; Konstantinos N Syrigos; George Fountzilas
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

Review 3.  Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis.

Authors:  Jinfang Zhang; Lixin Wan; Xiangpeng Dai; Yi Sun; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-02-22

Review 4.  Targeting Cdc20 as a novel cancer therapeutic strategy.

Authors:  Lixia Wang; Jinfang Zhang; Lixin Wan; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Pharmacol Ther       Date:  2015-04-04       Impact factor: 12.310

5.  Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.

Authors:  Cheng Long; Juan Chen; Hua Zhou; Tao Jiang; Xiang Fang; Dong Hou; Ping Liu; Hong Duan
Journal:  Cell Cycle       Date:  2019-01-22       Impact factor: 4.534

6.  CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression.

Authors:  Yiming Ding; Shuqing Yu; Zhaoshi Bao; Yanwei Liu; Tingyu Liang
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

7.  Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob/ob mice.

Authors:  Ashok Sharma; Shoshana M Bartell; Clifton A Baile; Bo Chen; Robert H Podolsky; Richard A McIndoe; Jin-Xiong She
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

Review 8.  Cdc20: a potential novel therapeutic target for cancer treatment.

Authors:  Zhiwei Wang; Lixin Wan; Jiateng Zhong; Hiroyuki Inuzuka; Pengda Liu; Fazlul H Sarkar; Wenyi Wei
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis.

Authors:  Qi Li; Hongmei Jia; Haowen Li; Chengya Dong; Yajie Wang; Zhongmei Zou
Journal:  Tumour Biol       Date:  2016-09-08

Review 10.  Mitotic chromosomal instability and cancer: mouse modelling of the human disease.

Authors:  Juan-Manuel Schvartzman; Rocio Sotillo; Robert Benezra
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.